Bellus Data Flop Catches Market By Surprise
Insights - Bellus announced Phase 2 data this morning and it was a major flop. The stock is down 75%. Bellus did not hit statistical significance in any of … Continue Reading
Premium: Read NowInsights
Taking Advantage of Fennec’s Rally Ahead of PDUFA
Insights - Fennec is up 50% since announcing their financing on April 30, 2020 @ 6.25/share. During this time, volume has picked up significantly, with 8.5M total … Continue Reading
Premium: Read Now
Market Starting to Realize Potential of Affimed’s Early Pipeline
Insights - Affimed (AFMD) has been on a tear lately as markets are starting to realize the potential of the company’s pipeline. It is trading above $4/share … Continue Reading
Premium: Read Now
Notes from Call With Essa Management
Insights - We had a call with Essa (EPIX) management earlier today. The initial thesis was that Essa’s second-generation drug would address the issues and potency limitations … Continue Reading
Premium: Read NowSecond Generation Candidate Could Be A Novel Breakthrough in Prostate Cancer
Insights - Essa Pharma (EPIX) is entering a second-gen drug, with a novel mechanism of action, into clinic for advanced prostate cancer The first-gen drug showed to … Continue Reading
Premium: Read Now
Milan Study: Giapreza Associated with Oxygen & MAP Improvements
Insights - Last Friday, San Raffaele Hospital in Milan, Italy, published data using La Jolla’s Giapreza in compassionate use. The study demonstrated that Giapreza was able to improve oxygenation … Continue Reading
Premium: Read NowRoche Picks Affimed as Its Horse In BCMA Race
Insights - Affimed & Genentech/Roche released their preclinical abstract for an anti-BCMA/CD16a bi-specific antibody in multiple myeloma today for the American Association of Cancer Research (AACR) conference. This affiliation confirms the … Continue Reading
Premium: Read Now